Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context

Summary: Background: Most cancer drugs enter the US market first. US Food and Drug Administration (FDA) approvals of new cancer drugs may influence regulatory decisions in other settings. The study examined whether characteristics of available evidence at FDA approval influenced time-to-marketing a...

Full description

Bibliographic Details
Main Authors: Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-de-Castro, Sabine Vogler, Elias Mossialos, Carla L. Tavares-de-Andrade, Huseyin Naci
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:The Lancet Regional Health. Americas
Subjects:
Brazil
United States
Pharmaceutical preparations
Health technology assessment
Cancer
Drug legislation
Online Access:http://www.sciencedirect.com/science/article/pii/S2667193X23000807

Internet

http://www.sciencedirect.com/science/article/pii/S2667193X23000807

Similar Items